In the 2026 China PIII, Haisco ranked 10th in Invention, rising 13 places from the previous year to enter the top 10, and 21st in Innovation. In 2025, the company continued to advance the launch and clinical adoption of innovative products in anesthesia and analgesia, while accelerating its R&D presence in autoimmune, respiratory and oncology areas. With important clinical progress in its differentiated pipeline, growing innovative drug sales and advancing overseas registrations, Haisco is consolidating its established specialties while progressively expanding the R&D and commercialization of innovative drugs across multiple therapeutic areas.

Haisco's operating growth in 2025 was driven mainly by the sales ramp-up of its marketed innovative drugs, and its improving commercial performance has built an operational foundation for future product development and market expansion...

Download the report to see the full company profile.